Adrenocortical carcinoma · NCT03604198
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
- Status
- ACTIVE_NOT_RECRUITING (ClinicalTrials.gov)
- Phase
- PHASE2
- Sponsor
- Corcept Therapeutics
- Registry records
- CTGOV NCT03604198 (ACTIVE_NOT_RECRUITING)Registry last updated 2026-11-03
Eligibility, line by line
| Verdict | In plain words (machine summary) | Registry text, verbatim | If unmet |
|---|---|---|---|
| inclusion inclusion · prior therapy · confidence 0.90 | Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome | "Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome" | |
| inclusion inclusion · other · confidence 0.30 | According to the Investigator's opinion will benefit from continuing treatment with relacorilant. | "According to the Investigator's opinion will benefit from continuing treatment with relacorilant." | |
| exclusion exclusion · prior therapy · confidence 0.30 | Premature discontinuation from a relacorilant parent study | "Premature discontinuation from a relacorilant parent study" | |
| exclusion exclusion · comorbidity · confidence 0.95 | Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism. | "Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism." |
Criteria extracted by claude-sonnet-5-5; 0 extracted quotes rejected for not matching the registry text.
Full eligibility text as the registry publishes it
Inclusion Criteria: * Major Inclusion Criteria: * Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome * According to the Investigator's opinion will benefit from continuing treatment with relacorilant. Exclusion Criteria: * Major Exclusion Criteria: * Premature discontinuation from a relacorilant parent study * Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
Routes in: how this trial is reached and paid for
US trials at ordinary hospitals: routine care is billed
In the US a sponsor funds the study drug and study-specific scans, but the routine care around them is billed to insurance. Without US cover that bill falls on you.
Cost is documented as the barrier that stops roughly 45 percent of US patients joining trials, before any question of being a non-resident. Eligibility on paper does not make a US site reachable. One email to the study coordinator asking what a non-resident without US insurance would be billed settles it either way.
Verify with: The study coordinator listed on the registry record
Ask first; potentially very high
Free patient navigation
myTomorrows (Amsterdam) provides medically trained, multilingual patient navigators who search ClinicalTrials.gov, EU CTIS and ISRCTN and can support a doctor through an expanded-access application. Free to patients and families.
A navigator keeps searching after any single page stops being current. Use it alongside this site, not instead of your oncologist.
Verify with: myTomorrows for patients
0
Sites (48)
Austria
- Site 14, Vienna
Canada
- Site 51, Nova Scotia
Germany
- Site 16, Munich
- Site 42, Würzburg
Israel
- Site 20, Ramat Gan
- Site 29, Tel Aviv
Italy
- Site 40, Ancona
- Site 44, Messina
- Site 25, Milan
- Site 21, Naples
- Site 48, Padova
- Site 52, Torino
Netherlands
- Site 33, Rotterdam
Poland
- Site 47, Krakow
- Site 45, Lublin
Romania
- Site 37, Bucharest
- Site 31, Bucharest
- Site 28, Bucharest
Spain
- Site 53, Alicante
- Site 18, Girona
- Site 17, Madrid
- Site 38, Málaga
- Site 19, Seville
United States
- Site 49, Phoenix
- Site 35, Stanford
- Site 39, Torrance
- Site 50, Miami
- Site 10, Atlanta
- Site 9, Chicago
- Site 1, Indianapolis
- Site 5, Metairie
- Site 27, Baltimore
- Site 13, Fall River
- Site 8, Ann Arbor
- Site 36, Rochester
- and 13 more